Literature DB >> 13678834

Mycobacterial efflux pumps and chemotherapeutic implications.

Miguel Viveiros1, Clara Leandro, Leonard Amaral.   

Abstract

The demonstration of the existence of active efflux pumps in mycobacteria raises the question of whether or not these can increase in number and activity rendering wild-type mycobacteria increasingly resistant to a given antibiotic. This could be a mechanism by which mutated resistant strains become better fit to the selective environment. Mycobacterium tuberculosis genome analysis reveals several genes encoding putative drug efflux pumps. During the course of tuberculosis chemotherapy many of these pumps might play a role in the survival of the mycobacterial populations. Compounds capable of inactivating these pumps could improve anti-tuberculous therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678834     DOI: 10.1016/s0924-8579(03)00208-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  17 in total

1.  LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis.

Authors:  Silvia Buroni; Giulia Manina; Paola Guglierame; Maria Rosalia Pasca; Giovanna Riccardi; Edda De Rossi
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

Review 2.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

4.  Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator.

Authors:  Marco Bellinzoni; Silvia Buroni; Francis Schaeffer; Giovanna Riccardi; Edda De Rossi; Pedro M Alzari
Journal:  J Bacteriol       Date:  2009-10-09       Impact factor: 3.490

Review 5.  Xenobiotic efflux in bacteria and fungi: a genomics update.

Authors:  Ravi D Barabote; Jose Thekkiniath; Richard E Strauss; Govindsamy Vediyappan; Joe A Fralick; Michael J San Francisco
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  2011

6.  Isolation and characterization of nontuberculous mycobacteria from patients with pulmonary tuberculosis in Ghana.

Authors:  Isaac Darko Otchere; Adwoa Asante-Poku; Stephen Osei-Wusu; Samuel Yaw Aboagye; Dorothy Yeboah-Manu
Journal:  Int J Mycobacteriol       Date:  2017 Jan-Mar

Review 7.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

8.  The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Authors:  Trudy H Grossman; Carolyn M Shoen; Steven M Jones; Peter L Jones; Michael H Cynamon; Christopher P Locher
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

9.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

10.  Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.

Authors:  Meeta J Advani; Imran Siddiqui; Pawan Sharma; Hemalatha Reddy
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.